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Translational Relevance 
Despite advances in prolonging survival of patients with metastatic NSCLC, treatment options after 
progression on second-line treatment remain an area of significant unmet medical need. Pemetrexed, 
gemcitabine, and ramucirumab are indicated for advanced NSCLC treatment. The addition of abemaciclib 
to single-agent chemotherapy or antiangiogenic therapy already approved in NSCLC may achieve 
additional clinical benefit. Preclinical studies in NSCLC models indicated potential additive benefit for 
the combination of single-agent treatments with abemaciclib. The JPBA phase 1 study demonstrated 
abemaciclib monotherapy activity in NSCLC, and recently, abemaciclib received Food and Drug 
Administration approval as single-agent or in combination with endocrine therapy for breast cancer. The 
objective of the JPBJ phase 1b study was to identify a tolerable abemaciclib dose, characterize its 
pharmacokinetics, and evaluate its antitumor activity when combined with single-agent chemotherapy or 
antiangiogenic therapy for the treatment of metastatic NSCLC. These results have potential as a 
foundation for future clinical development. 
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Abstract 
Introduction: Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and 6, has demonstrated 
preclinical activity in non–small cell lung cancer (NSCLC). A multicenter, nonrandomized, open-label 
phase 1b study was conducted to test safety, maximum tolerated dose (MTD), pharmacokinetics, and 
preliminary antitumor activity of abemaciclib in combination with other therapies for treatment in patients 
with metastatic NSCLC. 
Methods: An initial dose escalation phase was used to determine the MTD of twice-daily oral 
abemaciclib (150, 200 mg) plus pemetrexed, gemcitabine, or ramucirumab, followed by an expansion 
phase for each drug combination. Pemetrexed and gemcitabine were administered according to label. The 
abemaciclib plus ramucirumab study examined two dosing schedules. 
Results: The three study parts enrolled 86 patients; all received ≥1 dose of combination therapy. Across 
arms, the most common treatment-emergent adverse events were fatigue, diarrhea, neutropenia, decreased 
appetite, and nausea. The trial did not identify an abemaciclib MTD for the combination with pemetrexed 
or gemcitabine but did so for the combination of abemaciclib with days 1,8 ramucirumab (8mg/kg). 
Plasma sample analysis showed that abemaciclib did not influence the pharmacokinetics of the 
combination agents and the combinations agents did not affect abemaciclib exposure. The disease control 
rate was 57% for patients treated with abemaciclib-pemetrexed, 25% for abemaciclib-gemcitabine, and 
54% for abemaciclib-ramucirumab. Median progression-free survival was 5.55, 1.58, and 4.83 months, 
respectively.  
Conclusions: Abemaciclib demonstrated an acceptable safety profile when dosed on a continuous twice-
daily schedule in combination with pemetrexed, gemcitabine, or ramucirumab. Abemaciclib exposures 
remained consistent with those observed in single-agent studies. 
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Introduction 
Lung cancer is the most common cancer worldwide and the leading cause of cancer-related 
mortality (1). Non–small cell lung cancer (NSCLC) accounts for >80% of all lung cancer cases, with 
most patients initially diagnosed with advanced or metastatic disease (2). 
Platinum-based doublets are the standard first-line therapy for NSCLC in unselected patients; and 
in appropriate patients, these may be combined with bevacizumab, necitumumab, or pembrolizumab (3–
6). Patients with sensitizing mutations of EGFR or BRAF, or ALK or ROS-1 gene rearrangement are 
candidates for first-line therapy with targeted oral kinase inhibitors (2). 
Unfortunately, not all patients respond to first-line therapy and even patients who initially 
respond will likely relapse. Many patients are candidates for second-line and eventually third-line 
therapy. Available second-line treatment options in unselected patients include: docetaxel (with or 
without ramucirumab, or nintedanib in the European Union), and pemetrexed or gemcitabine if not 
previously used (2, 7–11). In addition, immune checkpoint inhibitors may be used following disease 
progression on or after platinum-based chemotherapy: pembrolizumab is indicated for selected patients 
with PD-L1 expression, and nivolumab and atezolizumab in unselected patients (12–14). 
Despite these advances in prolonging survival of patients with metastatic NSCLC, after 
progression on second-line treatment, there are few options. Third-line treatment continues to be 
challenging, and subsequent treatment options for patients with metastatic NSCLC remains an area of 
significant unmet medical need. 
Because cell cycle dysregulation occurs in >90% of lung cancers (15), disrupting the cell 
proliferation machinery may control the growth of advanced NSCLC. During the cell cycle, the G1 
restriction point controls entry into S phase (16). Cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) 
form a complex with D-type cyclins to advance the cell cycle through the G1 restriction point through 
phosphorylation of the Rb tumor suppressor protein (17). Inhibiting CDK4 and CDK6 prevents cell cycle 
progression, halting tumor growth and promoting senescence. 
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Abemaciclib is a selective and potent small molecule inhibitor of CDK4 and CDK6 with broad 
antitumor activity in preclinical models, acceptable physical and pharmacokinetic (PK) properties, and 
acceptable toxicity profile in nonclinical species (18,19). Preclinical data showed that KRAS-mutant 
NSCLC xenograft models (NCI-H2122, NCI-H358, and NCI-H441) had greater sensitivity to 
abemaciclib compared with models expressing a wild-type KRAS gene (NCI-H1975 and NCI-H1650) 
(20). In addition, preclinical studies conducted in KRAS-mutant NSCLC models (NCI-H441 and NCI-
H2122) indicated potential additivity when agents such as pemetrexed, gemcitabine, or DC101 (a mouse 
surrogate of ramucirumab) were combined with abemaciclib. In these studies, the combination therapies 
demonstrated greater tumor growth inhibition as well as longer duration of growth inhibition following 
treatment cessation compared with abemaciclib single-agent therapy (21). 
In the JPBA phase 1 study, single-agent abemaciclib showed acceptable safety/tolerability as well 
as early evidence of clinical activity in multiple tumor types, including patients with heavily pretreated 
metastatic NSCLC (20). Fatigue was the dose limiting toxicity across all tumor types. The most common 
treatment-emergent adverse events (TEAEs) were gastrointestinal and hematopoietic and were 
manageable with dose adjustments and supportive care. The disease control rate (DCR) among 
abemaciclib-treated patients was 49% (33 of 68 patients); 2 patients achieved partial responses. The DCR 
was greater in the KRAS-mutant population (55%) compared to that in the KRAS wild-type population 
(39%). 
Based on preclinical and clinical data, we conducted a multicenter phase 1b clinical study to test 
the safety and tolerability of oral abemaciclib combination therapy in patients with metastatic NSCLC. 
The secondary objectives of the study included determination of the pharmacokinetic profile for each 
combination therapy and assessment of antitumor activity. 
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Methods 
A multicenter, nonrandomized, open-label phase 1b trial enrolled patients previously treated for 
advanced/metastatic NSCLC. The study comprised multiple study parts, each with an initial dose 
escalation phase to determine the maximum tolerated dose (MTD) of abemaciclib plus pemetrexed (part 
A), gemcitabine (part B), or ramucirumab (part C), followed by an expansion phase for each study part. 
Part C also included investigation of an alternative ramucirumab dosing schedule. Two additional parts of 
the study, abemaciclib in combination with LY3023414 (PI3K/mTOR dual inhibitor) and 
pembrolizumab, have not been concluded and will be reported separately. 
This study was designed by the sponsor and was conducted in accordance with the Declaration of 
Helsinki ethical principles and International Conference on Harmonisation Guidelines for Good Clinical 
Practice. Site-specific institutional review boards or ethics committees approved the study protocol and 
amendments. All patients provided written informed consent. The study is registered at 
www.ClinicalTrials.gov (NCT02079636). 
Patients 
Key eligibility criteria included previously treated advanced/metastatic NSCLC, age ≥18 years, 
Eastern Cooperative Oncology Group performance status ≤1, and adequate hematologic and end organ 
function. Eligibility was not restricted based on molecular features; however, all patients with EGFR-
activating mutations or ALK alterations should have progressed on or after an EGFR or ALK tyrosine 
kinase inhibitor prior to enrollment. 
Part A required nonsquamous histology and one to three prior therapies, including one platinum-
based chemotherapy for advanced/metastatic NSCLC. Pemetrexed received as first-line or maintenance 
therapy must have been completed ≥3 months prior to study entry. Part B allowed any histological 
subtype and required one to three prior therapies for advanced/metastatic NSCLC. Part C allowed any 
histological subtype and required two to three prior therapies for advanced/metastatic NSCLC. Study 
allowed patients with measureable or nonmeasurable disease as defined by the Response Evaluation 
Criteria in Solid Tumors v1.1 (22). (The online appendix lists eligibility requirements.) 
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Treatments and MTD determination 
Table S1 (online appendix) outlines treatments and dose escalation scheme. During the dose 
escalation phase, cohorts of three to six patients enrolled at each of the planned dose levels. Abemaciclib 
was administered orally every 12 hours (Q12H) on days 1 through 21 of a 21-day cycle at 150 or 200 mg 
(the established single-agent MTD) until disease progression or other study discontinuation criteria were 
met. Pemetrexed (part A) and gemcitabine (part B) were administered according to label: day 1 for 
pemetrexed, days 1 and 8 for gemcitabine. Ramucirumab (part C) was administered on two different 
schedules on day 1 or on days 1 and 8 of a 21-day cycle. The ramucirumab days 1 and 8 regimen was 
developed based on pharmacokinetic simulations with the expectation to produce higher trough 
concentrations relative to the standard dosing regimen (22). Dose adjustments (omission and reduction) 
were permitted for each drug for specific toxicities (see online appendix for details). Patients discontinued 
from study treatment upon progression, unacceptable toxicity, or decision by the patient, physician, or 
sponsor. Post-study treatment evaluation occurred 30 ± 7 days from the last dose of study drug. 
Safety assessments guided the dose escalation phase during the first 21 days of treatment for all 
patients in each cohort. If no patient experienced a dose-limiting toxicity (DLT), dose escalation occurred 
to the next prespecified dose level. If one of three patients at any cohort experienced a DLT, then three 
additional patients were enrolled at that dose level. If a DLT was observed in ≥2 out of a maximum of six 
patients at any given dose, dose escalation ceased, and either the previous dose was declared the MTD for 
the combination therapy or additional patients were treated at the previous dose level to ensure <2 DLTs 
out of 6 patients occurred at that dose level. If more than 2 of 6 patients experienced a DLT at 150 mg 
Q12H, then the dose of abemaciclib was to be de-escalated to 100 mg Q12H. After the MTD for each 
combination therapy was identified in each study part in the dose escalation phase, each study part 
enrolled 12 additional patients for the confirmation phase of the study. Part C (ramucirumab) included a 
second dose escalation and a 6-patient confirmation cohort to evaluate an alternate dosing schedule for 
ramucirumab. 
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A DLT was defined as an adverse event (AE) occurring during cycle 1 of the dose escalation 
phase that was possibly related to either abemaciclib or the combination therapy and fulfilled any of the 
following criteria: grade 3 or 4 nausea, vomiting, diarrhea, or electrolyte disturbance persisting >2 days 
despite intervention, any other grade 3 or 4 nonhematological toxicity, grade 4 hematological toxicity that 
lasted longer than 5 days, grade 3 or 4 thrombocytopenia with evidence of bleeding, or febrile 
neutropenia. A DLT-equivalent toxicity (DET) was defined as an AE that would have met the criteria for 
DLT if it had occurred during cycle 1 of the dose escalation phase, but that occurred in a later cycle or 
during any cycle of the dose confirmation phase. 
Assessments 
Safety was assessed by AEs, DLTs, central laboratory tests, and local electrocardiograms. 
Adverse events were assessed for severity using the National Cancer Institute Common Terminology 
Criteria for Adverse Events (version 4.0) (23). Radiological tumor assessments were performed locally at 
baseline and then every 6 weeks thereafter until evidence of disease progression. Tumor response was 
assessed using Response Evaluation Criteria in Solid Tumors v1.1 (24). 
Pharmacokinetic samples were collected for all patients to measure concentrations of abemaciclib 
and its metabolites (LSN2839567, LSN3106729, and LSN3106726). Separate blood samples were 
collected to measure concentrations of pemetrexed (part A), gemcitabine plus its metabolite 2,2-
difluorodeoxyuridine (dFdU) (part B), and ramucirumab (part C). 
Pharmacokinetic samples were collected at predose, immediately postdose (cycle 1, day 1 only), 
and at 1, 2, 4, 6, 8, 10 hours postdose of abemaciclib on cycle 1, day 1 and on cycle 2, day 1 for 
abemaciclib and combination agents. Additional samples were collected at predose of cycle 1, day 8 (for 
abemaciclib and its metabolites, gemcitabine plus its metabolite, and ramucirumab) and cycle 1, day 15 
(for abemaciclib and its metabolites). Pharmacokinetic analyses were conducted on patients who had 
received at least 1 dose of study drug and had adequate samples collected. Plasma concentrations of 
abemaciclib and its metabolites were assayed at Q2 Solutions (Ithaca, New York). Plasma samples were 
analyzed for pemetrexed and gemcitabine and its metabolite at BASi (West Lafayette, IN USA). Serum 
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concentrations of ramucirumab were assayed at Intertek Pharmaceutical Services (San Diego, CA, USA). 
Pharmacokinetic parameter estimates were computed for abemaciclib, its metabolites, and whenever 
possible, for pemetrexed, gemcitabine, and ramucirumab). Pharmacokinetic parameters were computed 
by standard noncompartmental methods using WinNonlin (Professional Edition). The primary parameters 
for analysis were maximum concentration (Cmax) and area under the concentration-time curve from time 
zero to the last observation (AUC0–tlast). 
Statistical methods 
All patients who had at least 1 dose of study therapy were included in the analyses. Data were 
summarized by study part and dose group, as appropriate. For continuous variables, summary statistics 
included mean, median, standard deviation, and range. Categorical endpoints such as baseline 
characteristics, safety, and tumor response were summarized as frequency and percentages. Progression-
free survival (PFS) was analyzed using Kaplan-Meier methodology (25). Statistical Analyses System 
(SAS) V9 was used to analyze the data. 
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Results 
From April 2014 through March 2016, 10 centers in the United States and Spain enrolled 86 
patients with stage IV NSCLC in parts A, B, or C of the study based on prior therapy or histology. All 
patients were evaluable for safety and efficacy assessment. At the time of data cutoff (August 24, 2016), 
all patients except five (all on part C) had discontinued study treatment (Table S2, online appendix). The 
median age was 64–66 years across study parts (range: 43–83 years), with a median of 2 prior lines of 
therapy for advanced/metastatic disease (Table 1). 
All patients received abemaciclib (150 or 200 mg, twice daily) while on study in combination 
with either pemetrexed (part A), gemcitabine (part B), or ramucirumab (part C) on a 21-day cycle. 
Median number of cycles was 1.5–3.0 and range: 1–30 (Table S3, online appendix). Abemaciclib dose 
reductions occurred in 11 of 23 (48%) patients in part A, 8 of 24 (33%) patients in part B, and 14 of 39 
(36%) patients in part C. Dose omissions occurred in 15 patients in both parts A and B (65% and 63%, 
respectively), and in 21 patients (54%) in part C. The relative dose intensity of abemaciclib was 75–93% 
among the various treatment and dosage groups (Table S3, online appendix). 
Dose escalation and MTD determination 
Part A 
 The MTD was not reached for the abemaciclib-pemetrexed combination. At the 150-mg 
abemaciclib dose level, eight patients were enrolled; two of the initial three patients were deemed not 
evaluable and replaced. One patient experienced DLTs at 150 mg abemaciclib. No other DLTs occurred 
in part A at the 150-mg abemaciclib dose level (Table 2). At the 200-mg abemaciclib dose level, no DLTs 
were observed during cycle 1; one DET of grade 3 febrile neutropenia occurred during cycle 2. During 
cycle 2 of the 200-mg abemaciclib confirmation phase, one patient experienced grade 3 febrile 
neutropenia, and two patients experienced grade 4 neutropenia lasting longer than 5 days. 
Part B 
 The MTD was not reached for the abemaciclib-gemcitabine combination. At the 150-mg 
abemaciclib dose level, no DLTs reported (Table 2). At the 200-mg abemaciclib dose level, one DLT of 
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grade 3 fatigue occurred and four DETs, including grade 3 fatigue, grade 3 diarrhea, and two patients with 
grade 3 infections (grade 4 sepsis; grade 4 neutropenia/febrile neutropenia). 
Part C 
Part C evaluated two different dose schedules for ramucirumab. The first part C dosing schedule 
evaluated abemaciclib 150 or 200 mg twice daily in combination with ramucirumab 10 mg/kg on day 1 of 
a 21-day schedule (hereafter referred to as day 1 regimen). The second dosing schedule evaluated 
abemaciclib 150 mg twice daily in combination with ramucirumab 8 or 10 mg/kg on days 1 and 8 of a 21-
day schedule (hereafter referred to as day 1, 8 regimen). 
The MTD was not reached for the day 1 regimen. At the 150-mg abemaciclib dose level 
(ramucirumab 10 mg/kg day 1), four patients enrolled; one of the initial three patients was not evaluable 
and replaced. No DLTs were reported and one DET of grade 3 hyponatremia occurred during cycle 9. At 
the 200-mg abemaciclib dose level (ramucirumab 10 mg/kg day 1), two DLTs were reported in a single 
patient, grade 4 neutropenia and grade 4 leukopenia, and therefore the MTD was not achieved. DETs 
included grade 3 diarrhea, grade 4 hypokalemia, and grade 3 stomatitis (Table 2). 
For the day 1,8 regimen, 12 patients enrolled at the 8 mg/kg ramucirumab days 1, 8 dose level 
and 4 patients at the 10 mg/kg ramucirumab days 1, 8 dose level.  At the 8 mg/kg days 1, 8 dose level, 1 
DLT of grade 3 stomatitis and 2 DETs of grade 3 fatigue occurred. At the 10 mg/kg days 1, 8 dose level, 
4 DLTs occurred (3 patients), 1 DLT each of grade 4 embolism, and grade 3 myocardial infarction, and 
two DLTs of grade 3 fatigue. Thus, the MTD declared for part C second dosing schedule was abemaciclib 
150 mg twice daily and ramucirumab 8 mg/kg on days 1 and 8 of a 21-day cycle. 
Safety 
Part A 
 Among patient receiving the combination of abemaciclib and pemetrexed, the most common 
nonhematologic TEAEs (any grade) were fatigue (74%), diarrhea, (78%), decreased appetite (57%), 
nausea (48%), dyspnea (39%), increased blood creatinine (39%), stomatitis (30%), and vomiting (22%) 
(Table 3). The most common hematologic TEAEs (any grade) were neutropenia (65%), anemia (74%), 
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thrombocytopenia (44%), and leukopenia (30%). All-cause grade 3–4 TEAEs in >10% of patients were 
neutropenia (65%), anemia (26%), leukopenia (22%), dyspnea (22%), and thrombocytopenia (17%). 
Table S3 explains dose reduction information for part A. 
Part B 
 Abemaciclib plus gemcitabine yielded a similar pattern of TEAEs as observed in part A. The 
most common nonhematologic TEAEs (any grade) were fatigue (75%), nausea (67%), diarrhea (58%), 
decreased appetite (33%), vomiting (29%), dyspnea (21%), and increased blood creatinine (21%) (Table 
3). The most common hematologic TEAEs (any grade) were neutropenia (54%), thrombocytopenia (46%) 
anemia (42%), and leukopenia (21%). All-cause grade 3–4 TEAEs in >10% of patients were neutropenia 
(33%), anemia (25%), dyspnea (21%), and leukopenia (13%). High-grade diarrhea was greater in part B 
than part A (17% and 4%, respectively). Table S3 explains dose reduction information for part B. 
Part C 
 Among patients receiving the combination of abemaciclib and ramucirumab, across dose 
schedules, the most common nonhematologic TEAEs (any grade) were diarrhea (72%), fatigue (62%), 
nausea (49%), decreased appetite (41%), vomiting (31%), dyspnea (23%), and stomatitis (21%) (Table 3). 
The most common hematologic TEAEs (any grade) were neutropenia (23%), thrombocytopenia (21%), 
anemia (13%), and leukopenia (8%). All-cause grade 3 to 4 TEAEs in >10% of patients were fatigue 
(23%), diarrhea (10%), neutropenia (10%), and thrombocytopenia (10%). High-grade diarrhea was 
exclusively associated with the 200-mg abemaciclib dose level combined with ramucirumab 10 mg/kg 
(day 1 regimen). Table S3 explains dose reduction information for part C. 
Pharmacokinetics 
Figure 1 shows the mean plasma concentration-time profiles of abemaciclib and metabolites 
when administered in combination with other therapies, after a single abemaciclib dose, and at steady 
state after multiple twice-daily abemaciclib doses. Following 150-mg repeated doses (Table 4), the 
steady-state, geometric mean abemaciclib Cmax was 164 to 492 ng/mL and AUC(0–tlast) was 1300 to 3460 
(hr*ng/mL). Following the 200-mg repeated doses, the geometric mean abemaciclib Cmax was 227 to 483 
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ng/mL and AUC(0–tlast) was 1380 to 3460 (hr*ng/mL). Considering the high variability of the abemaciclib 
and metabolite pharmacokinetic parameters among the patient plasma samples, the exposure parameters 
for abemaciclib appeared similar among different combination therapies. 
Pharmacokinetic parameters for pemetrexed and mean plasma concentration-time profiles are 
presented in Table S4 and Figure S1, respectively (online appendix). Pharmacokinetic parameters for 
gemcitabine metabolite and mean plasma concentration-time profiles are presented in Table S5 and 
Figure S2, respectively (online appendix). Considering the long half-life of ramucirumab and the limited 
sampling schedule (up to 10 hours postdose), no pharmacokinetics parameters were estimated for 
ramucirumab. Figure S3 presents mean serum concentration-time profiles of ramucirumab. Taken 
together, the results of this study indicate that there is no effect of abemaciclib on the pharmacokinetics of 
combination agents and that combination agents have no effect on the pharmacokinetics of the 
abemaciclib. 
Response 
The addition of abemaciclib to pemetrexed, gemcitabine, or ramucirumab resulted in a response 
rate of 4–9% (all partial responses) (Table 5). However, the combination of abemaciclib with pemetrexed 
and ramucirumab resulted in a DCR of 57% and 54%, respectively. In contrast, the DCR the gemcitabine 
group was 25%. Median PFS results mirrored this trend. PFS for patients treated with abemaciclib plus 
pemetrexed was 5.55 months (95% CI: 1.81–10.05) and for patients treated with abemaciclib plus 
ramucirumab was 4.83 months (95% CI: 2.60–6.93), with five patients still receiving study treatment with 
abemaciclib plus ramucirumab at the time of analysis. In contrast, PFS for patients treated with 
abemaciclib plus gemcitabine was 1.58 months (95% CI: 1.15–4.24). 
Examination of treatment duration as a function of KRAS status (mutant versus wild type) did not 
reveal any relationship between patients receiving longer or shorter treatment and KRAS mutation (Figure 
S4, online appendix). Likewise, there was no apparent relationship between change in tumor size and 
KRAS status (Figure S5, online appendix). However, this interpretation was hampered by the large 
number of patients (51 of 85, 60%) with unknown KRAS status. 
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Discussion 
Treatment options for patients with metastatic NSCLC are limited considerably after progressing 
on or after first-line treatment. Among the available treatments, historical median PFS is only 2.0–4.5 
months for second-line and likely shorter for later lines of treatment (8, 26). This trial gathers initial data 
regarding possible new drug combinations for second-line (or additional lines) treatment for metastatic 
NSCLC. Based on preclinical and clinical data, we conducted a multicenter phase 1b clinical study to test 
the safety and tolerability of oral abemaciclib combination therapy in patients with metastatic NSCLC. 
Maximum tolerated dose was not reached for combinations of abemaciclib with gemcitabine or 
pemetrexed. Both combination treatments used a maximum abemaciclib dose of 200 mg twice daily. The 
combination of abemaciclib and ramucirumab 10 mg/kg on day 1 of a 21-day cycle did not reach a MTD. 
However, the day 1, 8 regimen declared an MTD at abemaciclib 150 mg twice daily plus ramucirumab 8 
mg/kg on days 1 and 8 of 21-day cycle. 
Abemaciclib was well tolerated in patients across study parts. The safety findings are consistent 
with AEs expected when combining abemaciclib with single-agent chemotherapy or antiangiogenic 
therapy. Treatment-related toxicities were generally manageable with dose adjustments and supportive 
care as needed. No unexpected safety signals or significant differences in AEs or serious adverse events 
were observed across study parts. Across combination treatments, 17–25% patients had all-cause high-
grade (3/4) fatigue. High-grade diarrhea appeared dose dependent and was well managed with 
antidiarrheal treatments and/or dose adjustments. In part A, one patient discontinued from treatment due 
to diarrhea. Overall, the incidence of AEs that resulted in treatment discontinuation of one or both study 
drugs was approximately 16%. In addition, safety findings for parts A and B are consistent with AEs 
expected when combining myelosuppressive agents with abemaciclib, resulting in an increased 
myelosuppressive effect (65% and 33% grade 3–4 neutropenia, respectively). As expected, the 
ramucirumab and abemaciclib combination had lower hematologic toxicity with a 23% overall incidence 
of neutropenia and 10% incidence of grade 3–4 neutropenia, which is consistent with the safety profile of 
single-agent abemaciclib (20). Across study parts, grade 3-4 TEAEs were generally reversible upon dose 
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omission and/or dose reduction. The overall safety and tolerability of abemaciclib combination therapy 
are important in this heavily pretreated metastatic NSCLC population. 
In general, abemaciclib can be dosed on a continuous twice-daily schedule when combined with 
single-agent chemotherapy or antiangiogenic therapy. The range of abemaciclib exposures achieved when 
combined with pemetrexed, gemcitabine, or ramucirumab is consistent with that observed in single-agent 
studies. There is no evidence of an effect of abemaciclib on the pharmacokinetics of pemetrexed, 
gemcitabine, or ramucirumab. The abemaciclib steady state exposures achieved in this current study have 
been associated with inhibition of Rb phosphorylation and G1 cell cycle arrest in xenograft models (19). 
Furthermore, when used as a single agent in patients with cancer, abemaciclib doses of 150 or 200 mg 
Q12H were associated with sustained biochemical inhibition (reduced phosphorylated Rb) and 
phenotypic G1 arrest (as assessed by reduced topoisomerase II alpha) expression in skin keratinocytes and 
tumor biopsies (20). 
Tumor response data for the combinations of pemetrexed and ramucirumab with abemaciclib 
demonstrated preliminary antitumor activity relative to the abemaciclib and gemcitabine combination. 
The DCR for abemaciclib plus pemetrexed was 57% (n = 23), abemaciclib plus gemcitabine was 25% (n 
= 24), and abemaciclib plus ramucirumab was 54% (n = 39). As expected, the median PFS data followed 
the same trend as the DCR, namely greater for the pemetrexed combination (5.55 months) and 
ramucirumab combination (4.83 months) across dosing schedules, and lesser for the gemcitabine 
combination (1.58 months).  No relationship was identified between KRAS mutation status and treatment 
duration or tumor response for the abemaciclib combinations explored among the 40% of patients with 
KRAS status by local testing. Earlier studies found that among abemaciclib-treated patients, the DCR was 
greater in the KRAS-mutant population compared with the KRAS wild-type population, due largely to an 
increase in stable disease (20). Additionally, KRAS-mutant NSCLC xenografts were found to be more 
sensitive to abemaciclib than wild-type NSCLC xenografts (20), also supporting the concept that the 
KRAS mutation identifies a population of NSCLC tumors sensitive to abemaciclib. However, no 
definitive efficacy conclusions can be reached due to the nonrandomized design and small sample size. 
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 In summary, this trial confirmed the safety and tolerability of abemaciclib combined with single-
agent chemotherapy or antiangiogenic therapy in previously treated unselected patients with 
advanced/metastatic NSCLC. 
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TABLES 
 
Table 1. Demographic profile of study populations 
 
 Part A 
Abemaciclib 
+Pemetrexed 
(N=23) 
Part B 
Abemaciclib 
+Gemcitabine 
(N=24) 
Part C 
Abemaciclib 
+Ramucirumab 
(N=39) 
Age, (years)    
     Median (range) 64 (43-83) 66 (43-80) 66 (43-82) 
     ≥65 years, n (%) 11 (48) 13 (54) 16 (62) 
Male, n (%) 14 (61) 13 (54) 23 (59) 
Race    
     American Indian 0 2 (8) 0 
     Asian 1 (4) 2 (8) 1 (3) 
     Black 1 (4) 1 (4) 0 
     White 21 (91) 19 (79) 38 (97) 
Country    
     Spain 9 (39) 6 (25) 13 (33) 
     USA 14 (61) 18 (75) 26 (67) 
ECOG PS    
     0 11 (48) 12 (50) 10 (26) 
     1 12 (52) 12 (50) 29 (74) 
Histology    
  Adenocarcinomaa 21 (91) 19 (79) 28 (76) 
  Large Cell Carcinoma 0 (0) 1 (4) 1 (3) 
  Squamous
b
 0 (0) 3 (13) 6 (16) 
  Lung, Other/Not otherwise specified
c
 2 (9) 1 (4) 2 (5) 
Median duration of disease from initial diagnosis,  
   months, (range) 
16 (4–50) 19 (6–119) 19 (6–102) 
Prior systemic therapies, median (range)    
     Any intent 2 (1–5) 2.5 (1–5) 2 (1–6) 
     Advanced/metastatic 2 (1–3) 2 (1–4) 2 (1–6) 
 
a 2 patients had incomplete data for Part C histology. Percentages are based on the number of patients with data. 
b Includes squamous and adenosquamous (predominantly squamous). Only patients with nonsquamous histology were eligible for 
Part A.  
c Includes: bronchioalveolar, adenosquamous (not specified), and lung – not otherwise specified. 
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Table 2. Dose-limiting toxicities and DLT-equivalent toxicities                                                                                                                                     
Abemaciclib dose (mg) 
No. of 
patients 
treated 
No. of 
patients 
with DLT 
or DET 
Cohort
a
 DLT or DET
b
 Cycle 
Part A: Abemaciclib + Pemetrexed   
150 mg Q12H 8 1 Escalation Acute kidney injury, Gr 3 
Blood creatinine increased, 
    Gr 3 
Fatigue, Gr 3 
1 
200 mg Q12H 15 4 Escalation Febrile neutropenia, Gr 3 2 
   Confirmation Febrile neutropenia, Gr 3 1 
   Confirmation Neutropenia, Gr 4 2 
   Confirmation Neutropenia, Gr 4 2 
Part B: Abemaciclib + Gemcitabine 
150 mg Q12 H 3 0 -- None -- 
200 mg Q12 H 21 5 Escalation Fatigue, Gr 3 1 
   Confirmation Fatigue, Gr 3 1 
   Confirmation Diarrhea, Gr 3 1 
   Confirmation Scrotal infection, Gr 3 1 
   Confirmation Neutropenia, Gr 4 
Sepsis, Gr 4 
Febrile neutropenia, Gr 4 
Lung infection, Gr 3 
2 
Part C: Abemaciclib + Ramucirumab   
150 mg Q12H +  
Ram 10 mg/kg day 1  
4 1 Escalation Hyponatraemia, Gr 3 9 
200 mg Q12H + 
Ram 10 mg/kg day 1  
19 3 Escalation Leukopenia, Gr 4 
Neutropenia, Gr 4 
1 
   Escalation Diarrhea, Gr 3 
Hypokalaemia, Gr 4 
2,3 
3 
   Confirmation Stomatitis Gr 3 1 
150 mg Q12H 
Ram 8 mg/kg days 1,8 
12 2 Escalation Stomatitis, Gr 3 
Fatigue, Gr 3 
1 
2 
   Confirmation Fatigue, Gr 2 2 
150 mg Q12H + 
Ram 10 mg/kg Days 1,8 
4 3 Escalation Embolism, Gr 4 
Fatigue, Gr 3 
1 
   Escalation Myocardial infarction, Gr 3 1 
   Escalation Fatigue, Gr 3 1,6 
 
a Each cohort listing represents a different patient. Some patients exhibited >1 DLT/DET or the same DLT/DET in >1 cycle. 
b A DLT was defined as one of a list of specific adverse events occurring during cycle 1 of the dose-escalation phase that was 
possibly related to abemaciclib or the combination therapy.  A DET was defined as an adverse event that would have met the 
criteria for DLT if it had occurred during cycle 1 for a patient enrolled in the dose-escalation phase, but that occurred in a later 
cycle or during any cycle for a patient in the dose-expansion phase.  
Abbreviations: DET, DLT-equivalent toxicity; DLT, dose-limiting toxicity; Gr, grade; No., number; Q12H, every 12 hours. 
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Table 3. Treatment-emergent adverse events regardless of causality, by grade and doses. 
Adverse event
a 
(N = 73) 
Part A: Abemaciclib + 
Pemetrexed (N = 23) 
Part B: Abemaciclib + 
Gemcitabine (N = 24) 
Part C: Abemaciclib + 
Ramucirumab (N = 39) 
Grade 3/4, n 
(%) 
All grades, 
n (%) 
Grade 3/4, n 
(%) 
Grade 3/4, 
n (%) 
All grades, 
n (%) 
Grade 3/4, n 
(%) 
Diarrhea 1 (4) 18 (78) 4 (17) 14 (58) 4 (10)    28 (72) 
Fatigue 4 (17) 18 (78) 6 (25) 18 (75) 9 (23)    24 (62) 
Nausea 1 (4) 11 (48) 2 (8) 16 (67) 2 (5) 21 (54) 
Neutropenia 15 (65) 15 (65) 8 (33) 13 (54) 4 (10) 9 (23) 
Anemia 7 (30) 18 (78) 6 (25) 10 (42) 1 (3) 5 (13) 
Decreased appetite 2(9) 13 (57) 1 (4) 9 (38) 2 (5)    16 (41) 
Thrombocytopenia 4 (17) 10 (44) 2 (8) 11 (46) 4 (10)    8 (21) 
Vomiting 0 (0) 5 (22) 0 (0) 8 33) 0 16 (41) 
Blood creatinine 
increased 
1 (4) 9 (39) 0 (0) 5 (21) 1 (3) 8 (21) 
Dyspnea 5 (22) 9 (39) 5 (21) 5 (21) 1 (3) 9 (23) 
Leukopenia 5 (22) 7 (30) 3 (13) 5 (21) 2 (5) 3 (8) 
Stomatitis 1 (4) 8 (35) 0 (0) 2 (8) 3 (8)    8 (21) 
Abemaciclib dose 
Adverse event, 
grades 3/4
a 
150 mg 
N = 8 
n (%) 
200 mg 
N = 15 
n (%) 
150 mg 
N = 3 
n (%) 
200 mg 
N = 21 
n (%) 
150 mg
b
 
N = 20 
n (%) 
200 mg
b
 
N = 19 
n (%) 
Diarrhea 0 (0) 1 (7) 0 (0) 4 (19) 0  4 (21) 
Fatigue 3 (38) 1 (7) 1 (33) 5 (24) 5 (25) 4 (21) 
Nausea 1 (13) 0 (0) 1 (33) 1 (5) 0 2 (11) 
Neutropenia 6 (75) 9 (60) 2 (67) 6 (29) 1 (5) 3 (16) 
Anemia 2 (25) 4 (27) 0(0) 6 (29) 0 1 (5) 
Decreased appetite 1 (13) 1 (7) 0 (0) 1 (5) 1 (5) 1 (5) 
Thrombocytopenia 2 (25) 2 (13) 0 (0) 2 (10) 1 (5) 3 (16)    
Vomiting 0 (0) 0 (0) 0 (0) 0 (0) 0 0 
Blood creatinine 
increased 
1 (13) 0 (0) 0 (0) 0 (0) 0 1 (5) 
Dyspnea 1 (13) 4 (27) 1 (33) 4 (19) 1 (5) 0 
Leukopenia 2 (25) 3 (20) 0 (0) 3 (15) 0 2 (11) 
Stomatitis 1 (13) 0 (0) 0 (0) 0 (0) 2 (10) 1 (5) 
 
aTEAEs that occurred in ≥30% (all grades) in ≥1 part of the study are listed. No grade 5 events occurred for the TEAEs listed. 
bAmong part C patients who received 150 mg abemaciclib, 4 patients received 10 mg/kg ramucirumab on day 1; 12 patients 
received 8 mg/kg ramucirumab on days 1 and 8; and 4 patients received 10 mg/kg ramucirumab on days 1 and 8. Patients who 
received 200 mg abemaciclib, received 10 mg/kg ramucirumab on days 1 and 8. 
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Table 4. Summary of abemaciclib exposure following oral administration every 12 hours in 
combination with therapies in patients with stage IV NSCLC. 
 
Geometric Mean (CV%)a 
Single dose Multiple dose 
Combination 
therapy 
Abemaciclibb 
Cmax 
(ng/mL) 
tmax
c 
(hr) 
AUC(0-last) 
(hr*ng/mL) 
Cmax 
(ng/mL) 
tmax
c 
(hr) 
AUC(0-last) 
(hr*ng/mL) 
Pemetrexed 
200 mg BID 
(n = 15) 
212 
(80) 
7.67 
(4.00–10.00) 
1050 
(95) 
483d 
(41) 
4.00d 
(0.00–9.67) 
3460d 
(49) 
150 mg BID 
(n = 8) 
114 
(67) 
6.09 
(3.82–9.73) 
654 
(66) 
146.40, 
183.23e 
7.88, 
0.00e 
1060, 
1600e 
100 mg BID 
(n =2) 
   
81.17, 
46.43e 
4.00, 
8.00e 
435, 
190e 
Gemcitabine 
200 mg BID 
(n = 19) 
206 
(73) 
7.85 
(3.92–10.00) 
1150 
(77) 
304f 
(66) 
6.85f 
(0.00–7.88) 
2100f 
(58) 
150 mg BID 
(n = 3) 
80.6 
(15) 
9.75 
(8.00–10.67) 
509 
(28) 
288g 
(71) 
5.53g 
(4.00–8.00) 
2060g 
(66) 
Ramucirumab 
10 mg/kg day 1 
200 mg BID 
(n = 19) 
195 
(86) 
6.00 
(2.08–8.00) 
919 
(112) 
227h 
(17) 
5.01h 
(0.00–8.00) 
1380h 
(144) 
150 mg BID 
(n = 4) 
312 
(11) 
6.00 
(4.33–8.17) 
1830 
(18) 
492i 
(117) 
1.00i 
(0.00–7.97) 
3460i 
(125) 
Ramucirumab 
10 mg/kg days 1, 8 
150 mg BID 
(n = 4) 
159 
(73) 
7.00 
(2.00–10.00) 
885 
(67) 
377.41I 
 
10.00I 
 
3420I 
 
100 mg BID 
(n = 1) 
   
86.14j 
 
6.00j 
 
534j 
 
Ramucirumab 
8 mg/kg days 1, 8 
150 mg BID 
(n = 12) 
103 
(97) 
7.91 
(4.00–8.00) 
549 
(108) 
246 
(86) 
2.00 
(0.00–8.00) 
1730 
(95) 
 
aGeometric mean and geometric CV% are provided for n ≥ 3; otherwise, actual values are provided. 
bPatients were started on 150 or 200 mg; later, doses were reduced to 100 mg due to dose reductions. 
cMedian and range are provided for tmax. 
dN = 9. 
eN = 2. 
fN = 6. 
gN = 4. 
hN = 8. 
iN = 5. 
jN = 1. 
Abbreviations: AUC(0–last), area under the concentration time curve from time 0 to last observed concentration; Cmax, maximum 
plasma concentration; CV, coefficient of variation; n, number of observations. 
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Table 5. Summary of efficacy measures 
 
Part A: 
Abemaciclib + 
Pemetrexed 
(N = 23) 
Part B: 
Abemaciclib + 
Gemcitabine 
(N = 24) 
Part C: 
Abemaciclib + 
Ramucirumab 
(N = 39) 
Best overall response, n (%)
a
   
Complete response (CR) 0 (0) 0 (0) 0 (0) 
Partial response (PR) 1 (4) 1 (4) 2 (5) 
Stable disease (SD)  12 (52) 5 (21) 19 (49) 
Progressive disease (PD) 3 (13) 9 (38) 6 (15) 
Unknown 7 (30) 9 (38) 12 (31) 
Disease control rate  
   (CR + PR + SD) 
13 (57) 6 (25) 21 (54) 
Progression-free survival   
Number of events, n (%) 11 (48) 15 (63) 19 (49) 
Number of patients censored,  
   n (%) 
12 (52) 9 (38) 20 (51) 
Median PFS, months  
   (95% CI) 
5.55 (1.81, 10.05) 1.58 (1.15, 4.24) 4.83 (2.60, 6.93) 
 
a
Response criteria RECIST1.1 was used to determine response. Radiological tumor assessments were performed locally at 
baseline and then every 6 weeks thereafter until evidence of disease progression. Confirmation of complete or partial response 
was required for determination of best overall response. Stable disease required at least one post-baseline measurement at a 
minimum interval of 6 weeks after the first dose. 
 
Abbreviations: CI, confidence interval; n, number of observations; PFS, progression-free survival. 
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FIGURE LEGEND 
Figure 1. Abemaciclib plasma concentration over time. Mean plasma concentrations of abemacilcib is 
shown over time following single dose (left panel) and multiple dose (right panel) administration of 
abemaciclib (100, 150, or 200 mg) every 12 hours in combination with other agents as treatment for 
patients with stage IV NSCLC. 
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